|
|
Other links at Articles > Hematology-Oncology |
| 1. |
Does Switch Maintenance Benefit Patients With NSCLC?
|
|
|
In patients with partial response to initial therapy, is there benefit to switching to a new agent for maintenance therapy? Dr. Mark Kris examines studies that address this question. Medscape Hematology-Oncology
|
| 4. |
Translating p53 into the Clinic
|
|
|
The TP53 gene is mutated in half of reported cancer cases and the p53 pathway is often partially inactivated in the remaining half. This Review discusses the future of p53-based therapy. Nature Reviews Clinical Oncology
|
|
|